CY1108301T1 - Συνθεση περιλαμβανουσα αναστολεα αποακετυλασης ιστονης εμφανιζουσα διφασικη απελευθερωση - Google Patents

Συνθεση περιλαμβανουσα αναστολεα αποακετυλασης ιστονης εμφανιζουσα διφασικη απελευθερωση

Info

Publication number
CY1108301T1
CY1108301T1 CY20081100925T CY081100925T CY1108301T1 CY 1108301 T1 CY1108301 T1 CY 1108301T1 CY 20081100925 T CY20081100925 T CY 20081100925T CY 081100925 T CY081100925 T CY 081100925T CY 1108301 T1 CY1108301 T1 CY 1108301T1
Authority
CY
Cyprus
Prior art keywords
distribution
differental
bison
applicable
free
Prior art date
Application number
CY20081100925T
Other languages
English (en)
Inventor
Hanshermann Dr Franke
Peter Dr Lennartz
Alexander B Dr Maurer
Bernd Dr Hentsch
Sascha Dr Hövelmann
Elke Dr Martin
Original Assignee
Topotarget Germany Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Topotarget Germany Ag filed Critical Topotarget Germany Ag
Publication of CY1108301T1 publication Critical patent/CY1108301T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
    • A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
    • A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Otolaryngology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε μία διαθέσιμη δια του στόματος γαληνική σύνθεση βαλπροϊκού οξέως ή παραγώγων του η οποία εμφανίζει μία συγκεκριμένη διφασική φαρμακοκινητική κατανομή βελτιστοποιημένη για μέγιστη αναστολή των αποακετυλασών ιστόνης σε ένα θεραπευτικό περιβάλλον. Αυτή η συγκεκριμένη γαληνική σύνθεση είναι σχεδιασμένη για την αγωγή κακοηθών παθήσεων και παθήσεων σχετιζόμενων με την υποακετυλίωση των ιστονών ή στις οποίες η επαγωγή υπερακετυλιώσεως έχει μία ευεργετική δράση, π.χ. δι' επαγωγής της διαφοροποιήσεως και/ή της αποπτώσεως. Λόγω της διφασικής κατανομής απελευθερώσεως η προκύπτουσα φαρμακοκινητική μορφή είναι ικανή να αναστέλλει αποτελεσματικότερα τα ένζυμα στόχους HDAC και εν συνεχεία να επάγει υπερακετυλίωση των ιστονών κατά ταχύ καθώς και μακράς διαρκείας τρόπο. Αυτή η κατανομή εξασφαλίζει την αποτελεσματική ρύθμιση της εκφράσεως ενός επιθυμητού γονιδίου στόχου το οποίο συμβάλλει στο θεραπευτικό όφελος.
CY20081100925T 2004-04-30 2008-08-28 Συνθεση περιλαμβανουσα αναστολεα αποακετυλασης ιστονης εμφανιζουσα διφασικη απελευθερωση CY1108301T1 (el)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04010333A EP1591109B1 (en) 2004-04-30 2004-04-30 Formulation comprising histone deacetylase inhibitor exhibiting biphasic release

Publications (1)

Publication Number Publication Date
CY1108301T1 true CY1108301T1 (el) 2014-02-12

Family

ID=34924816

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081100925T CY1108301T1 (el) 2004-04-30 2008-08-28 Συνθεση περιλαμβανουσα αναστολεα αποακετυλασης ιστονης εμφανιζουσα διφασικη απελευθερωση

Country Status (19)

Country Link
US (1) US20070232528A1 (el)
EP (1) EP1591109B1 (el)
JP (1) JP4789927B2 (el)
CN (1) CN1980647B (el)
AT (1) ATE399539T1 (el)
AU (1) AU2005237251B2 (el)
BR (1) BRPI0509340A (el)
CA (1) CA2564877A1 (el)
CY (1) CY1108301T1 (el)
DE (1) DE602004014723D1 (el)
DK (1) DK1591109T3 (el)
ES (1) ES2308065T3 (el)
MX (1) MXPA06012568A (el)
NZ (1) NZ550879A (el)
PL (1) PL1591109T3 (el)
PT (1) PT1591109E (el)
SI (1) SI1591109T1 (el)
WO (1) WO2005105055A1 (el)
ZA (1) ZA200608714B (el)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040883A2 (en) 1998-02-11 1999-08-19 Faller Douglas V Compositions and methods for the treatment of cystic fibrosis
EP2502649A1 (en) 2005-02-03 2012-09-26 TopoTarget UK Limited Combination therapy using HDAC inhibitors and erlotinib for treating cancer
KR101329437B1 (ko) 2005-05-13 2013-11-14 토포타겟 유케이 리미티드 Ｈｄａｃ 억제제의 약학 제형
AU2006280062A1 (en) * 2005-08-10 2007-02-22 Novartis Ag Method of use of deacetylase inhibitors
JP5377968B2 (ja) * 2005-11-10 2013-12-25 トポターゲット ユーケー リミテッド 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
BRPI0520686A2 (pt) * 2005-11-16 2009-05-19 Univ Mexico Nacional Autonoma uso de agentes modificantes de transcriptoma associado a quimioterapia ou radioterapia contra o cáncer
US20070207950A1 (en) * 2005-12-21 2007-09-06 Duke University Methods and compositions for regulating HDAC6 activity
DE102006006532B4 (de) * 2006-02-10 2007-11-08 Biogenerics Pharma Gmbh Pharmazeutische Zubereitung
EP1839656A1 (en) * 2006-03-31 2007-10-03 TopoTarget Germany AG Use of valproic acid for the topical treatment of mild to moderate acne vulgaris
US20100137239A1 (en) 2006-04-24 2010-06-03 Gloucester Pharmaceuticals Gemcitabine combination therapy
WO2007146730A2 (en) 2006-06-08 2007-12-21 Gloucester Pharmaceuticals Deacetylase inhibitor therapy
EP2056808A4 (en) * 2006-08-28 2009-12-23 Univ California SMALL MOLECULAR AMPLIFIER OF HORMONTHERAPY FOR BREAST CANCER
US8088951B2 (en) * 2006-11-30 2012-01-03 Massachusetts Institute Of Technology Epigenetic mechanisms re-establish access to long-term memory after neuronal loss
CA2671649A1 (en) * 2006-12-06 2008-06-12 Sapporo Medical University Potentiation of cellular immunity using histone deacetylase (hdac) inhibitors
ES2529147T3 (es) * 2006-12-26 2015-02-17 Pharmacyclics, Inc. Método para usar los inhibidores de la histona deacetilasa y monitorear biomarcadores en la terapia de combinación
AU2007342028B2 (en) 2006-12-29 2013-06-13 Celgene Corporation Purifiction of romidepsin
CA2574531C (en) * 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
WO2008090534A1 (en) * 2007-01-26 2008-07-31 Berand Limited Methods and compositions for inhibition of excessive weight gain, reduction of inappropriate eating behaviours and inhibition of binge eating for the treatment of obesity
EP2170311A4 (en) * 2007-05-16 2011-10-19 Avalon Pharmaceuticals COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING AUTOIMMUNE DISEASES
CN101868446A (zh) * 2007-09-25 2010-10-20 托波塔吉特英国有限公司 某些异羟肟酸化合物的合成方法
MX2010009642A (es) * 2008-03-07 2010-09-22 Topotarget As Metodos de tratamiento utilizando infusion continua prolongada de belinostat.
DE102008047515A1 (de) * 2008-09-12 2010-03-25 Eberhard-Karls-Universität Tübingen Universitätsklinikum Behandlung einer demyelinisierenden Erkrankung
GB0900555D0 (en) * 2009-01-14 2009-02-11 Topotarget As New methods
WO2011038110A2 (en) * 2009-09-23 2011-03-31 The General Hospital Corporation Methods of treating metabolic disease
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
JP2013509441A (ja) 2009-10-30 2013-03-14 マサチューセッツ インスティテュート オブ テクノロジー 記憶／認知および不安障害の処置のためのｃｉ−９９４およびジナリンの使用
WO2011063164A2 (en) * 2009-11-18 2011-05-26 Steady Sleep Rx Co., Inc. Sustained release cannabinoid medicaments
EP2509418A4 (en) * 2009-12-08 2013-03-20 Hemaquest Pharmaceuticals Inc METHODS AND REGIMES AT LOW DOSE FOR TREATING RED GLOBULAR DISORDERS
WO2011113013A2 (en) 2010-03-11 2011-09-15 Hemaquest Pharmaceuticals, Inc. Methods and compositions for treating viral or virally-induced conditions
RU2607634C2 (ru) 2010-07-12 2017-01-10 Селджин Корпорейшн Твердые формы ромидепсина и их применение
US8859502B2 (en) 2010-09-13 2014-10-14 Celgene Corporation Therapy for MLL-rearranged leukemia
US9018176B2 (en) * 2010-12-02 2015-04-28 Susan Perrine Inducers of hematopoiesis and fetal globin production for treatment of cytopenias and hemoglobin disorders
AU2012226586B2 (en) 2011-03-09 2017-04-13 Cereno Scientific Ab Compounds and methods for improving impaired endogenous fibrinolysis using histone deacetylase inhibitors
UA110853C2 (uk) 2011-09-13 2016-02-25 Фармасайклікс, Інк. Лікарські форми інгібітора гістондеацетилази у комбінації з бендамустином та їхнє застосування
WO2013039956A2 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating mood disorders
AU2013202506B2 (en) 2012-09-07 2015-06-18 Celgene Corporation Resistance biomarkers for hdac inhibitors
AU2013202507B9 (en) 2012-11-14 2015-08-13 Celgene Corporation Inhibition of drug resistant cancer cells
NZ630311A (en) 2013-12-27 2016-03-31 Celgene Corp Romidepsin formulations and uses thereof
GB201417828D0 (en) 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
FR3025105B1 (fr) * 2014-09-02 2018-03-02 Centre Hospitalier Universitaire Pontchaillou Utilisation de l'acide valproique ou de ses derives dans le traitement des insuffisances en hepcidine et de leurs consequences
EP3445343A1 (en) 2016-04-21 2019-02-27 Valcuria AB Composition and method for pretreating cancer
BR112018072602A2 (pt) * 2016-05-03 2019-02-19 Spectrix Therapeutics, LLC composições e métodos para prover hormônio da tiroide ou análogos do mesmo
US11819482B2 (en) 2017-08-29 2023-11-21 Conrig Pharma Aps Composition comprising suplatast tosilate
CN109705057B (zh) * 2017-10-25 2023-05-30 成都先导药物开发股份有限公司 组蛋白去乙酰化酶抑制剂及其制备方法与用途
CN108992442A (zh) * 2018-07-12 2018-12-14 上海交通大学医学院附属瑞金医院 Ms-275在制备促进胰岛素分泌药物中的用途
CN110882250B (zh) * 2018-09-07 2022-09-13 上海市生物医药技术研究院 Scriptaid在制备治疗弱精症药物和试剂及器械器皿中的应用
JP7541319B2 (ja) * 2019-04-18 2024-08-28 共和薬品工業株式会社 吸湿性成分を含むコーティング錠
AU2020283590A1 (en) 2019-05-31 2022-01-20 Viracta Subsidiary, Inc. Methods of treating virally associated cancers with histone deacetylase inhibitors
CN110652506A (zh) * 2019-11-09 2020-01-07 福建医科大学附属第一医院 三醋酸甘油酯在制备预防和治疗抑郁症药物中的用途
CN111358777A (zh) * 2020-02-24 2020-07-03 军事科学院军事医学研究院环境医学与作业医学研究所 一种提高外周血单个核细胞线粒体功能的方法和应用
WO2022005012A1 (ko) * 2020-06-30 2022-01-06 고려대학교 산학협력단 Sirt7 억제제를 포함하는 알레르기 질환 예방 또는 치료용 약학적 조성물
CN112998101A (zh) * 2021-04-20 2021-06-22 上海舒泽生物科技研究所 一种人体衰老kat7基因的抑制剂固体饮料及其制备方法
CN114306259B (zh) * 2021-11-18 2023-06-06 江苏宇锐医药科技有限公司 一种丙戊酸钠双层缓释片及其制备方法
CN115094142B (zh) * 2022-07-19 2024-05-28 中国医学科学院肿瘤医院 用于诊断肺肠型腺癌的甲基化标志物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK152744C (da) * 1982-08-13 1988-10-31 Benzon As Alfred Fremgangsmaade til fremstilling af et farmaceutisk peroralt polydepotpraeparat
IT1215726B (it) * 1988-01-18 1990-02-22 Alfa Wassermann Spa Formulazioni galeniche a cessione programmata.
IL96311A (en) * 1989-12-01 1995-05-26 Abbott Lab Medications with delayed release
IT1255522B (it) * 1992-09-24 1995-11-09 Ubaldo Conte Compressa per impiego terapeutico atta a cedere una o piu' sostanze attive con differenti velocita'
US6287598B1 (en) * 1993-05-28 2001-09-11 Alza Corporation Method for providing sustained antiepileptic therapy
FR2772615B1 (fr) * 1997-12-23 2002-06-14 Lipha Comprime multicouche pour la liberation instantanee puis prolongee de substances actives
US6419960B1 (en) * 1998-12-17 2002-07-16 Euro-Celtique S.A. Controlled release formulations having rapid onset and rapid decline of effective plasma drug concentrations
BR0007360A (pt) * 1999-12-23 2001-08-14 Johnson & Johnson Composição de liberação controlada
EP1170008A1 (en) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
JP4632166B2 (ja) * 2001-01-31 2011-02-16 日本ポリウレタン工業株式会社 リグノセルロース系熱圧成形体用接着剤組成物、及びそれを用いた熱圧成形体の製造方法

Also Published As

Publication number Publication date
DK1591109T3 (da) 2008-10-06
JP2007535518A (ja) 2007-12-06
MXPA06012568A (es) 2007-04-30
ZA200608714B (en) 2008-07-30
DE602004014723D1 (de) 2008-08-14
EP1591109A1 (en) 2005-11-02
CN1980647B (zh) 2010-08-18
JP4789927B2 (ja) 2011-10-12
PT1591109E (pt) 2008-09-05
US20070232528A1 (en) 2007-10-04
PL1591109T3 (pl) 2008-11-28
CN1980647A (zh) 2007-06-13
WO2005105055A1 (en) 2005-11-10
BRPI0509340A (pt) 2007-09-18
ATE399539T1 (de) 2008-07-15
CA2564877A1 (en) 2005-11-10
NZ550879A (en) 2010-05-28
ES2308065T3 (es) 2008-12-01
AU2005237251B2 (en) 2010-11-04
AU2005237251A1 (en) 2005-11-10
SI1591109T1 (sl) 2008-10-31
EP1591109B1 (en) 2008-07-02

Similar Documents

Publication Publication Date Title
CY1108301T1 (el) Συνθεση περιλαμβανουσα αναστολεα αποακετυλασης ιστονης εμφανιζουσα διφασικη απελευθερωση
MX2020011528A (es) Inhibidores heterociclicos sustituidos de ptpn11.
DE60313624D1 (de) Derivate von heteroarylnitrilverbindungen
CY1117995T1 (el) Δευτεριωμενα παραγωγα κατεχολαμινης και φαρμακα που περιεχουν τις εν λογω ενωσεις
ATE469674T1 (de) 5-aminolävulinsäure-derivate zur behandlung von akne
CY1116405T1 (el) Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης
EA200802223A1 (ru) 1,5-дифенилпиразолы ii в качестве ингибиторов hsp90
ATE530544T1 (de) Benzyl-substituierte positive allosterische chinolon-m1-rezeptormodulatoren
EA201070127A1 (ru) Способы лечения легочной гипертензии, родственных заболеваний и нарушений и композиции для их осуществления
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
EA201290184A1 (ru) Бензодиазепиновый ингибитор бромодомена
DE602006015851D1 (de) Positive allosterische chinolon-m1-rezeptormodulatoren
EA201000365A1 (ru) Гетероциклические амиды, пригодные для лечения злокачественного новообразования и псориаза
EA201290191A1 (ru) N1-ПИРАЗОЛОСПИРОКЕТОНОВЫЕ ИНГИБИТОРЫ АЦЕТИЛ-KoA-КАРБОКСИЛАЗЫ
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
EA201291099A1 (ru) Новые иммуномодуляторные и противовоспалительные соединения
MX336774B (es) Moduladores alostericos positivos de receptores m1 de la quinolina amida.
UY30097A1 (es) Usos terapeuticos de inhibidores de rtp801
UY31027A1 (es) Derivados de tetrahidroindol y tetrahidroindazol
BR0316606A (pt) Derivados de aminoindazóis e sua utilização como inibidores de quinases
EA201000007A1 (ru) Производные индазоламида
ATE554084T1 (de) N-hydroxyacrylamidverbindungen
MA32240B1 (fr) Inhibiteurs de désacétylases b à base d'hydroxamate
EA201100872A1 (ru) Производные хиназолинамида
EA201000362A1 (ru) Производные 1,3-дигидроизоиндола